JP6483858B2 - サソリ毒耐熱合成ペプチド - Google Patents

サソリ毒耐熱合成ペプチド Download PDF

Info

Publication number
JP6483858B2
JP6483858B2 JP2017554073A JP2017554073A JP6483858B2 JP 6483858 B2 JP6483858 B2 JP 6483858B2 JP 2017554073 A JP2017554073 A JP 2017554073A JP 2017554073 A JP2017554073 A JP 2017554073A JP 6483858 B2 JP6483858 B2 JP 6483858B2
Authority
JP
Japan
Prior art keywords
scorpion
heat
resistant
synthetic peptide
svhrsp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017554073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529626A (ja
JP2018529626A5 (enExample
Inventor
杰 趙
杰 趙
韶 李
韶 李
万琴 張
万琴 張
Original Assignee
大連医科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大連医科大学 filed Critical 大連医科大学
Publication of JP2018529626A publication Critical patent/JP2018529626A/ja
Publication of JP2018529626A5 publication Critical patent/JP2018529626A5/ja
Application granted granted Critical
Publication of JP6483858B2 publication Critical patent/JP6483858B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017554073A 2016-08-08 2016-12-26 サソリ毒耐熱合成ペプチド Active JP6483858B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610645111.7A CN106220713B (zh) 2016-08-08 2016-08-08 一种蝎毒耐热合成肽及其用途
CN201610645111.7 2016-08-08
PCT/CN2016/112078 WO2018028117A1 (zh) 2016-08-08 2016-12-26 一种蝎毒耐热合成肽及其用途

Publications (3)

Publication Number Publication Date
JP2018529626A JP2018529626A (ja) 2018-10-11
JP2018529626A5 JP2018529626A5 (enExample) 2018-12-27
JP6483858B2 true JP6483858B2 (ja) 2019-03-13

Family

ID=57547837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554073A Active JP6483858B2 (ja) 2016-08-08 2016-12-26 サソリ毒耐熱合成ペプチド

Country Status (7)

Country Link
US (2) US10442837B2 (enExample)
EP (1) EP3505530B1 (enExample)
JP (1) JP6483858B2 (enExample)
CN (1) CN106220713B (enExample)
CA (1) CA2984569C (enExample)
ES (1) ES2945407T3 (enExample)
WO (1) WO2018028117A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106220713B (zh) * 2016-08-08 2017-09-01 大连医科大学 一种蝎毒耐热合成肽及其用途
CN109232718B (zh) * 2018-11-09 2020-04-14 泰安市启航生物科技有限公司 一种合成肽sp2及其应用
CN111647051B (zh) * 2019-03-04 2022-02-01 中国医科大学 一种基于钠通道结构的短肽及其应用
CN111896651B (zh) * 2020-07-30 2021-04-23 山东大学 一种白眉蝮蛇蛇毒类凝血酶特征多肽及其应用
CN114028537B (zh) * 2021-11-27 2024-03-29 上海万锦医药科技有限公司 一种含有svhrsp蝎毒肽的药物组合物及其制备方法
CN117224655B (zh) * 2023-09-14 2024-05-14 大连医科大学 蝎毒耐热合成肽(svhrsp)在制备治疗肠道炎症的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1171595C (zh) * 2001-02-19 2004-10-20 大连高新园区全国高技术产业化微生态中试基地 获取无毒有效蝎毒的生产工艺及由该工艺制备的治疗癫痫的药物
US20030235902A1 (en) * 2001-12-13 2003-12-25 Kazuhiko Ishikawa Heat-resistant thioredoxin and related enzymes
CN100465272C (zh) * 2002-01-18 2009-03-04 中国科学院上海有机化学研究所 重组东亚马氏钳蝎毒rBmKaIT1的基因工程
CN100516217C (zh) * 2004-09-22 2009-07-22 山西大学 一种人工合成的蝎氯离子通道神经毒素基因-rBmK CTa
US20070191272A1 (en) * 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
CN1817902A (zh) * 2006-03-07 2006-08-16 山西大学 一种重组蝎昆虫毒素及其可溶性表达和纯化方法
CN101450966B (zh) * 2007-11-29 2012-06-27 武汉摩尔生物科技有限公司 一种抗耐药菌的多肽及用途
CN101284870B (zh) * 2008-06-03 2011-09-14 武汉大学 一种抗麻疹病毒和人免疫缺陷病毒的多肽及用途
CN103304630B (zh) * 2012-03-07 2014-09-17 中国科学院大连化学物理研究所 东亚钳蝎蝎毒中的gpcr活性多肽及其提取分离和应用
CN104341495A (zh) 2013-07-31 2015-02-11 张万琴 一种蝎毒耐热多肽和制备方法及其应用
CN106220713B (zh) * 2016-08-08 2017-09-01 大连医科大学 一种蝎毒耐热合成肽及其用途

Also Published As

Publication number Publication date
ES2945407T3 (es) 2023-07-03
CA2984569C (en) 2019-10-22
EP3505530A1 (en) 2019-07-03
JP2018529626A (ja) 2018-10-11
US10442837B2 (en) 2019-10-15
US10870680B2 (en) 2020-12-22
US20180066019A1 (en) 2018-03-08
CA2984569A1 (en) 2018-02-08
EP3505530A4 (en) 2020-04-29
US20200002381A1 (en) 2020-01-02
WO2018028117A1 (zh) 2018-02-15
EP3505530B1 (en) 2023-02-22
CN106220713B (zh) 2017-09-01
CN106220713A (zh) 2016-12-14

Similar Documents

Publication Publication Date Title
JP6483858B2 (ja) サソリ毒耐熱合成ペプチド
KR101491860B1 (ko) Ｍｕ-코노톡신 펩티드 및 국소 마취제로서 그의 용도
US11802140B2 (en) Treatment of ischemia
US10717771B2 (en) Treatment of ischemia
Chen et al. Effects of bee venom peptidergic components on rat pain-related behaviors and inflammation
CN104277092A (zh) 用于预防和/或治疗老年性痴呆的β片层阻断肽
CN107779437B (zh) 自噬诱导剂作为微管稳定药物促进神经再生的用途
CN114605497A (zh) 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
CN104083420A (zh) 牛膝活性提取物及其制备方法与用途
JP4777344B2 (ja) 南米ガラガラヘビ（ｃｒｏｔａｌｕｓｄｕｒｉｓｓｕｓｔｅｒｒｉｆｉｃｕｓｓｎａｋｅｓ）毒液に由来する鎮痛ペプチドの類似化合物、これらの使用、組成物、調製と精製の方法
CN112194730B (zh) 一种多肽ti-16及其用途
Yan et al. Deoxyschizandrin attenuates Aβ1–42-induced cognitive impairments through up-regulation of AMPA receptors in mice
Wang et al. Ginsenoside Rg1 alleviates chronic stress-induced depression in rats by targeting Cx43-YAP axis
D'Este Identificazione di nuovi mediatori e vie di segnale che promuovono la rigenerazione nervosa periferica
Boubekka Investigation of the Effects of Rutin and Some Other Similar Plant Components on Analgesia Related Neuronal Electrophysiological Parameters in Primary Cell Culture
CN118806876A (zh) 眼镜蛇神经毒素及其制剂在制备预防和/或治疗阿尔茨海默病的药物中的用途
Jin Development of a small alpha-synuclein-knockdown peptide as a potential therapy for Parkinson’s disease
HK1137765A1 (en) β -SHEET BLOCKING PEPTIDES FOR PREVENTING AND/OR TREATING ALZHEIMER’S DISEASE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181016

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190214

R150 Certificate of patent or registration of utility model

Ref document number: 6483858

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250